Search results for "cortico"

showing 10 items of 693 documents

Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD

2000

ss(2)-Agonists and corticosteroids or theophylline can interact to produce beneficial effects on airway function in asthma, but this has not been established in COPD.Eighty patients with well-controlled COPD were randomized to receive 3 months of treatment in one of four treatment groups: (1) salmeterol, 50 microg bid; (2) salmeterol, 50 microg, plus fluticasone propionate, 250 microg bid; (3) salmeterol, 50 microg, plus fluticasone propionate, 500 microg bid; and (4) salmeterol, 50 microg, plus titrated theophylline bid. At each visit, a dose-response curve to inhaled salbutamol was constructed using a total cumulative dose of 800 microg.A gradual increase in FEV(1) was observed with each …

MalePulmonary and Respiratory Medicinemedicine.drug_classPharmacologyCritical Care and Intensive Care MedicineFluticasone propionateTheophyllineForced Expiratory VolumeBronchodilatorAdministration InhalationmedicineHumansAlbuterolTheophyllineLung Diseases ObstructiveGlucocorticoidsSalmeterol XinafoateAgedFluticasoneDose-Response Relationship Drugbusiness.industryDrug SynergismAdrenergic beta-AgonistsMiddle AgedMetered-dose inhalerBronchodilator AgentsAndrostadienesAnesthesiaSalbutamolFluticasoneCorticosteroidDrug Therapy CombinationFemaleSalmeterolCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data

2010

SummaryBackgroundLong-term oral corticosteroid (OCS) therapy is associated with significant burden on patients and healthcare resources; treatments that may help reduce their use are important to improve asthma management.MethodsFrench and German clinicians prescribing omalizumab for >16 weeks to patients with severe persistent allergic asthma collected OCS use data. OCS use was recorded at baseline and at a non-specific time point beyond 16 weeks from initiation of omalizumab. The number of asthma exacerbations (FEV1 16 weeks. Of these, 166 (48.0%) were receiving maintenance OCS (France, n = 64; Germany, n = 102). Following omalizumab therapy, 84 (50.6%) patients on OCS at baseline reduced…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyDatabases Factualmedicine.drug_classAllergic asthmaOmalizumabOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin EAdrenal Cortex HormonesOral administrationGermanyInternal medicineOral corticosteroidsRespiratory HypersensitivityHumansMedicineAnti-Asthmatic AgentsAnti-IgEAsthmabiologybusiness.industryRespiratory diseaseAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicSurgeryHospitalizationbiology.proteinPrednisoloneCorticosteroidFemaleFrancebusinessmedicine.drugRespiratory Medicine
researchProduct

Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: A case-control study

2015

Background: In outpatients with chronic obstructive pulmonary disease (COPD), blood eosinophilia is considered as a biomarker of response to systemic corticosteroid therapy. However, little is known on whether blood eosinophilia is also predictive of positive clinical outcome in severe acute exacerbations of COPD requiring hospitalization. We hypothesized that blood eosinophil-positive severe acute exacerbations of COPD differ from eosinophil-negative ones in terms of response to therapy and clinical outcomes. Methods: To test our experimental hypothesis, we retrospectively analyzed medical records of patients with COPD admitted to our ward because of severe exacerbation, over a two-year pe…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness IndexdosageGlucocorticoids/administration &ampPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineEosinophiliaSeverity of illnessmedicineHumansBiological markers/bloodCOPDEosinophiliaPharmacology (medical)030212 general & internal medicineIntensive care medicineAgedRetrospective StudiesAged 80 and overCOPDbusiness.industryMedical recordBiochemistry (medical)Case-control studyRetrospective cohort studyMiddle Agedmedicine.diseaserespiratory tract diseasesEosinophilsHospitalizationTreatment Outcome030228 respiratory systemCase-Control StudiesInclusion and exclusion criteriaLength of stayBiomarker (medicine)Femalemedicine.symptombusinessPulmonary Pharmacology & Therapeutics
researchProduct

GOLD 2017 treatment pathways in ‘real life’: An analysis of the DACCORD observational study

2017

Abstract Introduction The 2017 update to the Global Initiative for Obstructive Lung Disease (GOLD) strategy document includes recommendations for treatment intensification or step-down in chronic obstructive pulmonary disease (COPD), although recognises that limited supporting information is available. DACCORD is an ongoing observational, non-interventional study, recruiting patients following COPD maintenance treatment change or initiation, a subset of whom were receiving a long-acting β2-agonist (LABA) plus a long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) on entry. Since there were no requirements in terms of prior medication (and no washout before commencing LABA/L…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationmedicine.drug_classMuscarinic AntagonistsQuinolonesMaintenance ChemotherapyPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinePharmacotherapyAdrenal Cortex HormonesGermanyInternal medicineAdministration InhalationmedicineHumansddc:610Longitudinal StudiesProspective Studies030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAgedCOPDbiologybusiness.industryDisease ManagementMiddle AgedLamabiology.organism_classificationmedicine.diseaseGlycopyrrolateObstructive lung diseaseDrug Combinations030228 respiratory systemIndansPractice Guidelines as TopicCritical PathwaysDisease ProgressionPhysical therapyIndacaterolCorticosteroidDrug Therapy CombinationFemaleObservational studybusinesshormones hormone substitutes and hormone antagonistsmedicine.drugRespiratory Medicine
researchProduct

D-dimer concentrations in acute urticaria in children

2021

Introduction: Urticaria is a clinical entity presenting as wheals, angioedema, or both simul-taneously. Elevated D-dimer levels were reported in the course of chronic spontaneous urticaria. Data regarding D-dimer levels in acute urticaria in children are limited. Objectives: To assess potential associations between duration of glucocorticosteroid (GCS) therapy and D-dimer concentrations in children with acute urticaria. Patients, materials, and methods: Hospital records of 106 children (59 females), aged 5.57 ± 4.91 years, hospitalized in 2014–2018 were analyzed retrospectively. The study group consisted of pediatric patients admitted to the hospital due to severe acute urticaria resistant …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtypediatricsAdolescentUrticariaImmunologyD-dimersglucocorticosteroidsFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicinechildrenAmbulatory careInternal medicineWhite blood cellD-dimerHumansImmunology and AllergyMedicinePlateletIn patientacute urticariaChildGlucocorticoidsRetrospective StudiesAcute urticariaAngioedemabusiness.industryDisease ManagementInfantGeneral Medicinemedicine.anatomical_structure030228 respiratory systemChild PreschoolAcute DiseaseAntihistaminic drugsFemalemedicine.symptombusinessBiomarkers030215 immunologyAllergologia et Immunopathologia
researchProduct

In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) comp…

2019

Recent evidence indicates that AZD8999 (LAS190792), a novel muscarinic acetylcholine receptor antagonist and β2-adrenoceptor agonist (MABA) in development for chronic respiratory diseases, induces potent and sustained relaxant effects in human bronchi by adressing both muscarinic acetylcholine receptors and β2-adrenoceptor. However, the anti-inflammatory effects of the AZD8999 monotherapy or in combination with corticosteroids are unknown. This study investigates the anti-inflammatory effects of AZD8999 in monotherapy and combined with fluticasone propionate in neutrophils from healthy and chronic obstructive pulmonary disease (COPD) patients. Peripheral blood neutrophils from healthy and C…

MalePulmonologyNeutrophilsPhysiologyAnti-Inflammatory AgentsPharmacologyPathology and Laboratory MedicineBiochemistryPulmonary Disease Chronic ObstructiveWhite Blood CellsGlucocorticoid receptorAnimal CellsMuscarinic acetylcholine receptorMedicine and Health SciencesPost-Translational ModificationPhosphorylationReceptorImmune ResponseMultidisciplinaryPharmaceuticsQRDrug SynergismMiddle AgedReceptors MuscarinicHealthy VolunteersBody FluidsChemistryBloodPhysical SciencesQuinolinesMedicineDrug Therapy CombinationFemalemedicine.symptomCellular TypesAnatomymedicine.drugResearch ArticleSignal TransductionAgonistTransmembrane Receptorsmedicine.drug_classp38 mitogen-activated protein kinasesChronic Obstructive Pulmonary DiseaseImmune CellsScienceImmunologyInflammationMuscarinic AntagonistsThiophenesFluticasone propionateSigns and SymptomsDrug TherapyCyclohexanesDiagnostic MedicinemedicineHumansAdrenergic beta-2 Receptor AgonistsAgedInflammationBlood CellsDose-Response Relationship Drugbusiness.industryAntagonistChemical CompoundsBiology and Life SciencesProteinsCell BiologyAcetylcholine ReceptorsFluticasoneMuscarinic Acetylcholine ReceptorsReceptors Adrenergic beta-2PropionatesbusinessReceptor Antagonist TherapyPLoS ONE
researchProduct

Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving mode…

2011

PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT(3)) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids. METHODS: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting …

MaleQuinuclidinesmedicine.medical_treatmentCINVCHOPGastroenterologyDexamethasoneSettore MED/15 - Malattie Del SangueAntineoplastic Combined Chemotherapy ProtocolsSerotonin 5-HT3 Receptor AntagonistsProspective StudiesAged 80 and overLymphoma Non-HodgkinPalonosetronNauseaMiddle AgedEmesisPalonosetronTreatment OutcomeOncologyAnesthesiaCHOP CINV Emesis Nausea NHL PalonosetronVomitingFemaleOriginal Articlemedicine.symptomCHOP-CINV; emesis; nausea; NHL; Palonosetronmedicine.drugAdultmedicine.medical_specialtyVomitingNauseamedicine.drug_classNHLYoung AdultInternal medicinemedicineHumansAntiemeticGlucocorticoidsAgedChemotherapybusiness.industryIsoquinolinesmedicine.diseaseNon-Hodgkin's lymphomaAntiemeticsbusinessCHOPChemotherapy-induced nausea and vomiting
researchProduct

Affinity and efficacy of racemic, (+)-, and (−)-methacholine in muscarinic inhibition of [3H]-noradrenaline release

1985

The right postganglionic sympathetic nerves of rat isolated perfused hearts (previously loaded with [3H]-noradrenaline) were stimulated electrically with 10 trains of 10 pulses at 10 Hz. The inhibition by methacholine of stimulation-evoked [3H]-noradrenaline overflow into the perfusate (determined in the presence of corticosterone, desipramine, phentolamine, and propranolol) was taken as a measure for activation of presynaptic muscarinic receptors. The evoked [3H]-noradrenaline overflow was inhibited by (+)-, racemic, and (-)-methacholine in a reversible and concentration-dependent manner. The concentration causing 50% inhibition (IC50) was 0.1, 0.26, and 65 microM, respectively, resulting …

MaleReceptor complexSympathetic Nervous SystemIntrinsic activityPhenoxybenzamineStereochemistryPhysostigminePropranololIn Vitro TechniquesPropylbenzilylcholine MustardNorepinephrineMuscarinic acetylcholine receptormedicineAnimalsMethacholine CompoundsDrug InteractionsReceptorMethacholine ChlorideNeuronsPharmacologyPhenoxybenzamineChemistryHeartRats Inbred StrainsStereoisomerismReceptors MuscarinicElectric StimulationRatsDissociation constantSynapsesMethacholineCorticosteroneResearch Articlemedicine.drugBritish Journal of Pharmacology
researchProduct

Steroid hormone receptor analysis in human melanoma and non-malignant human skin

1982

MaleReceptors SteroidSkin NeoplasmsSteroid hormone receptorbusiness.industryReceptors Cell SurfaceNon malignantHuman skinDermatologyReceptors GlucocorticoidReceptors EstrogenImmunologyCancer researchHumansMedicineFemaleHuman melanomaProgestinsbusinessMelanomaSkinBritish Journal of Dermatology
researchProduct

Effect of recurrent yohimbine on immediate and post-hoc behaviors, stress hormones, and energy homeostatic parameters

2013

Evidence from experimental models has suggested that acute activation of brain stress and anxiety pathways impacts subsequent behaviors that are mediated or modulated by limbic circuitry. There have been limited investigations of prior or chronic activation of these pathways on subsequent limbic-mediated behaviors. In this study, we tested whether recurrent administration of the anxiogenic compound yohimbine (YOH) could have post-injection effects on brain activation, stress hormones, and performance in sucrose self-administration and startle response paradigms. Rats received six injections across two weeks of either 2mg/kg YOH or saline. Behavioral evaluation confirmed the continued effica…

MaleReflex Startlemedicine.medical_specialtyStartle responseHippocampusExperimental and Cognitive PsychologyAdrenocorticotropic hormoneMotor ActivityAmygdalaArticleEatingBehavioral Neurosciencechemistry.chemical_compoundAdrenocorticotropic HormoneDietary SucroseCorticosteroneInternal medicinemedicineAnimalsPsychotropic Drugsmedicine.diagnostic_testBody WeightBrainYohimbineFeeding BehaviorImmunohistochemistryRatsYohimbineVentral tegmental areamedicine.anatomical_structureEndocrinologyAnxiogenicchemistryCorticosteronePsychologyProto-Oncogene Proteins c-fosStress Psychologicalmedicine.drugPhysiology & Behavior
researchProduct